Singapore markets open in 9 hours

Galapagos NV (GLPG)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
52.12-0.38 (-0.72%)
As of 11:54AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close52.50
Open52.75
Bid51.96 x 900
Ask52.10 x 900
Day's range51.91 - 52.79
52-week range48.66 - 129.03
Volume56,568
Avg. volume242,363
Market cap3.44B
Beta (5Y monthly)0.37
PE ratio (TTM)N/A
EPS (TTM)-3.46
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est79.80
  • Zacks

    Galapagos (GLPG) Concludes Enrollment in Crohn's Disease Study

    Galapagos (GLPG) finishes enrollment in phase III study evaluating filgotinib for Crohn's Disease. The company also assumes sole responsibility for the DIVERSITY study.

  • Motley Fool

    Galapagos NV (GLPG) Q2 2021 Earnings Call Transcript

    GLPG earnings call for the period ending June 30, 2021.

  • Motley Fool

    Here's Why Galapagos Stock Is Falling Today

    Shares of Galapagos (NASDAQ: GLPG), a biopharmaceutical company, are under pressure following clinical trial readouts for a couple of new drug candidates in phase 1 studies. Disappointing results from the company's Toledo program pushed the stock 13.1% lower as of 3:52 p.m. EDT on Thursday. Following the implosion of Jyseleca in the U.S., Galapagos has leaned on its early clinical-stage pipeline to get attention from investors.